ASTRO 2017: Practice-Changing Abstracts in Prostate, Renal Cancers

Video
Conference|American Society for Radiation Oncology Annual Meeting (ASTRO)

This video highlights potentially practice-changing studies on genitourinary cancers presented at the 2017 ASTRO Annual Meeting.

In this video, Gerard Morton, MD, of Odette Cancer Centre in Canada, discusses selected studies on the treatment of genitourinary cancers presented at the 2017 American Society for Radiation Oncology (ASTRO) Annual Meeting, held September 24–27 in San Diego.

Morton was the discussant for a session on genitourinary cancer that featured the following abstracts, which were selected for their importance in potentially changing practice:

• Abstract 1: A prospective phase ii trial of transperineal ultrasound-guided brachytherapy for locally recurrent prostate cancer after external beam radiotherapy (NRG/RTOG0526): Initial report of late toxicity outcome

• Abstract 330: Individual patient data meta-analysis of SBRT kidney: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK)

• Abstract 336: Five-year outcomes of a phase I dose escalation study using stereotactic body radiosurgery for patients with clinically localized prostate cancer

• Abstract 1089: The use of chemotherapy instead of radiation therapy does not reduce incidence of second cancers in survivors of early stage seminoma: A population based study from British Columbia

• Abstract 282: Extremely dose escalated radiotherapy improves cancer-specific survival compared with radical prostatectomy or conventionally dose-escalated radiotherapy in Gleason score 9-10 prostate adenocarcinoma: a multi-institutional analysis of 1,403 patients

Recent Videos
Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.
Increased use of systemic therapies, particularly among patients with high-risk node-negative NSCLC, were observed following radiotherapy.
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
A prospective trial may help affirm ctDNA as a non-invasive option of predicting responses to radiotherapy among those with gynecologic cancers.
Interest in novel therapies to improve outcomes initiated an investigation of the use of immunotherapy in early-stage non-small cell lung cancer.
ctDNA reductions or clearance also appeared to correlate with a decrease in disease burden during the pre-boost phase of radiotherapy.
Investigators evaluated ctDNA as a potentially noninvasive method to predict response to radiotherapy among those with gynecologic malignancies.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Raymond B. Mailhot, MD, MPH, discussed how radiation therapy can impact education and survivorship for pediatric survivors of brain tumors.
Related Content
The VIOLETTE trial, which used OBT-fusion technology for patients with focal ablation of the prostate by microwave needles, released interim results.

VIOLETTE Trial Shows Precise Planning in Prostate Cancer Microwave Ablation

Tim Cortese
November 22nd 2024
Article

The VIOLETTE trial, which used OBT-fusion technology for patients with focal ablation of the prostate by microwave needles, released interim results.

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

Exploring New Possibilities in Kidney Cancer Detection and Therapy

Karl Semaan, MD, MSc ;Neil J. Shah, MBBS;Bradley McGregor, MD
July 22nd 2024
Podcast

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

Addressing Gaps in Education for Non–Clear Cell RCC

Addressing Gaps in Education for Non–Clear Cell RCC

ONCOLOGY Staff
November 19th 2024
Article

A panel discussed on RCC and the differentiation in the identification and treatment of clear and non-clear cell RCC.

AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.

Leveraging Artificial Intelligence Evolutions in Prostate Cancer Care

James B. Yu, MD, MHS, FASTRO;Julian C. Hong, MD, MS
July 1st 2024
Podcast

AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.

Stereotactic body radiotherapy showed noninferior biochemical or clinical failure compared with standard radiotherapy in select patients with prostate cancer.

SBRT Emerges as Viable Treatment for Localized Prostate Cancer

Tim Cortese
November 12th 2024
Article

Stereotactic body radiotherapy showed noninferior biochemical or clinical failure compared with standard radiotherapy in select patients with prostate cancer.

The Evolving Landscape of Prostate Cancer Management

The Evolving Landscape of Prostate Cancer Management

Maha Hussain, MD
October 28th 2024
Article

Maha Hussain, MD, FACP, FASCO, spoke about BRCA testing and ctDNA as diagnostic tools and PSMA-imaging and -targeted approaches in prostate cancer.